Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
June 20, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
June 04, 2014 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients
May 23, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 23, 2014) - Nuvilex (OTCQB: NVLX) is calling it a "two pronged attack" on pancreatic cancer, but investors may be calling it an "end-around" or another avenue of...
Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist
April 03, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 3, 2014) - That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it...